Try
Rigel Pharmaceuticals Inc. Common Stock
RIGLUnited States
5 filed reports · 256 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 935 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 765 | Dec 2025 |
Financial data
256 concepts · 1,700 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial241 concepts · 1,480 facts · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Other comprehensive income availableforsale securities adjustment net of tax portion attributable to parent13 · Dec 2023 to Jun 2026
- Stock issued during period value share based compensation13 · Dec 2023 to Jun 2026
- Valuation allowances and reserves balance13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)12 · Dec 2023 to Jun 2026
- Costs and expenses12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Operating lease cost12 · Dec 2023 to Jun 2026
- Prepaid research and development costs12 · Dec 2024 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- Accrued research and development11 · Dec 2023 to Jun 2026
- Amortization of intangible assets11 · Dec 2023 to Mar 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect11 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization11 · Dec 2023 to Jun 2026
- Increase decrease in accounts payable11 · Dec 2023 to Jun 2026
- Increase decrease in accounts receivable11 · Dec 2023 to Jun 2026
Segment10 concepts · 127 facts · Dec 2023 to Jun 2026
- Commercial related expenses13 · Dec 2023 to Jun 2026
- Consultants and third-party services13 · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)13 · Dec 2023 to Jun 2026
- Interest income expense net13 · Dec 2023 to Jun 2026
- Labor and related expense13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Outside clinical trial related expenses13 · Dec 2023 to Jun 2026
- Revenue13 · Dec 2023 to Jun 2026
- Segment reporting other item amount13 · Dec 2023 to Jun 2026
- Income tax expense benefit10 · Dec 2023 to Jun 2026
Product5 concepts · 93 facts · Mar 2021 to Jun 2026
- Revenue84 · Dec 2023 to Jun 2026
- Government assistance operating income3 · Dec 2023 to Dec 2025
- Revenue recognized3 · Mar 2021 to Jun 2025
- Company's percentage of development costs2 · Dec 2025 to Mar 2026
- Financing liability interest accretion discount rate1 · Dec 2025
Segments
220 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments2 members · 127 facts
- Single Reportable87 · Dec 2023 to Dec 2025
- One Operating40 · Mar 2025 to Jun 2026
Product or service13 members · 93 facts
- Contract Revenues From Collaborations12 · Dec 2023 to Jun 2026
- Discounts And Allowances12 · Dec 2023 to Jun 2026
- Gross Product12 · Dec 2023 to Jun 2026
- Product12 · Dec 2023 to Jun 2026
- Royalty Delivery Of Drug Supplies And Others12 · Dec 2023 to Jun 2026
- Development Milestones9 · Dec 2023 to Jun 2026
- License5 · Dec 2023 to Dec 2025
- Release Of Share Cost Liability5 · Dec 2023 to Jun 2026
- Ocadusertib4 · Jun 2025 to Mar 2026
- Fostamatinib3 · Dec 2023 to Dec 2025
- Government Contract3 · Dec 2023 to Dec 2025
- Non Central Nervous System Penetrant Intellectual Property2 · Mar 2021 to Dec 2021
- Release Of Cost Share Liability2 · Jun 2025 to Sep 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 4, 2026
- FY2026 Q1May 6, 2026
- FY2025 Q4Mar 3, 2026
- FY2025 Q3Nov 4, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 17, 2026) and refreshed every few hours.